Search results
Results from the WOW.Com Content Network
Johnson & Johnson interventional vascular technology subsidiary Cordis has finished its acquisition of stent maker Flexible Stenting Solutions. Financial terms of the deal weren't disclosed ...
Cordis Corporation Announces Two-Year Results from the STROLL Trial Trial Assesses the Safety and Efficacy of the S.M.A.R.T.® Vascular Stent Systems in the Superficial Femoral Artery BRIDGEWATER ...
Cordis Corporation Announces One-Year Results from the STROLL Trial Trial Assesses the Safety and Efficacy of the S.M.A.R.T.® Nitinol Self-Expandable Stent System in the Superficial Femoral ...
Cordis is an American international medical company that develops and manufactures medical devices for diagnostics and interventional procedures to treat coronary and peripheral vascular diseases. The company operates in the North America, Europe, Middle East, Africa, Asia-Pacific, and Latin America markets.
Fischell went on to invent the implantable insulin pump (MiniMed, spun off from Pacesetter Systems in 1985), numerous coronary stents used to open clogged arteries (IsoStent merged with Cordis, in turn purchased by Johnson & Johnson), [11] and two feedback systems that provide early warning of epileptic seizures (NeuroPace) and heart attacks ...
The first two drug-eluting stents to be utilized were the paclitaxel-eluting stent and the sirolimus-eluting stent, both of which have received approval from the U.S. Food and Drug Administration. Most current FDA-approved drug-eluting stents use sirolimus (also known as rapamycin), everolimus and zotarolimus.
For premium support please call: 800-290-4726 more ways to reach us
The abdominal aneurysm extends down to the common iliac arteries in about 25%-30% of patients. In such cases, the iliac limbs can be extended into the external iliac artery to bypass a common iliac aneurysm. Alternatively, a specially designed endograft, (an iliac branch device) can be used to preserve flow to the internal iliac arteries.